| Autolus Therapeutics Plc ADR (AUTL) | |||
|---|---|---|---|
| 4.08 -0.11 (-2.63%) | 05-06 16:00 | ||
| Open: | 4.25 | Pre. Close: | 4.19 |
| High: | 4.318 | Low: | 4.03 |
| Volume: | 2,021,174 | Market Cap: | 710(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 5.83  One year: 6.82 |
| Support: | Support1: 3.61 Support2: 3.00 |
| Resistance: | Resistance1: 4.99 Resistance2: 5.84 |
| Pivot: | 4.28 |
| Moving Averages: | MA(5): 4.01  MA(20): 4.50 MA(100): 5.77 MA(250): 4.10 |
| MACD: | MACD(12,26): -0.43 Signal(12,26,9): -0.44 |
| %K %D: | %K(14,3): 30.81 %D(3): 25.76 |
| RSI: | RSI(14): 34.53 |
| 52-Week: | High: 7.45 Low: 1.79 Change(%): 117.0 |
| Average Vol(K): | 3-Month: 1755 10-Days: 3325 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 4.322 - 4.345 | 4.345 - 4.361 |
| Low: | 3.981 - 4.003 | 4.003 - 4.02 |
| Close: | 4.045 - 4.082 | 4.082 - 4.111 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AUTL ] has closed above bottom band by 36.1%. Bollinger Bands are 16.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | |
| Shares Float (M) | 265.93 |
| % Held by Insiders | 91180000.00 |
| % Held by Institutions | 18.04 |
| Shares Short (K) | 3150 |
| Shares Short Prior Month (K) | |
| Stock Financials | |
|---|---|
| EPS | -168960000.000 |
| Book Value (p.s.) | |
| Profit Margin | |
| Operating Margin | -10.00 |
| Return on Assets (ttm) | 337.3 |
| Return on Equity (ttm) | -25.4 |
| Qtrly Rev. Growth | 1700000.0 |
| Gross Profit (p.s.) | -51.813 |
| Sales Per Share | -52.648 |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | -1.20 |
| Operating Cash Flow (M) | |
| Levered Free Cash Flow (M) | -145.59 |
| Stock Valuation | |
|---|---|
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | -0.08 |
| Price to Cash Flow | 12.30 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | 4070000.000 |
